Provided by Tiger Trade Technology Pte. Ltd.

Babson Capital Corporate Investors

20.58
-0.2100-1.01%
Post-market: 20.580.00000.00%16:10 EST
Volume:27.34K
Turnover:563.89K
Market Cap:421.86M
PE:13.18
High:20.86
Open:20.62
Low:20.51
Close:20.79
52wk High:25.24
52wk Low:18.60
Shares:20.50M
Float Shares:- -
Volume Ratio:2.01
T/O Rate:- -
Dividend:1.70
Dividend Rate:8.26%
EPS(TTM):1.56
EPS(LYR):1.74
ROE:9.13%
ROA:5.63%
PB:1.21
PE(LYR):11.80

Loading ...

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

GlobeNewswire
·
Dec 04

New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

GlobeNewswire
·
Dec 03

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

GlobeNewswire
·
Nov 28

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

GlobeNewswire
·
Nov 25

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

GlobeNewswire
·
Nov 14

Barings Corporate Investors reports Q3 net investment income of $7.1 million

Reuters
·
Nov 14

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

GlobeNewswire
·
Nov 05

India Inflation Cools Further in September

MT Newswires Live
·
Oct 14

LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”

GlobeNewswire
·
Oct 14

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia

GlobeNewswire
·
Sep 24

How a new three-minute memory test can help spot Alzheimer's disease

Switzer
·
Sep 18

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

GlobeNewswire
·
Sep 03

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

GlobeNewswire
·
Sep 03

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

GlobeNewswire
·
Aug 30

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

GlobeNewswire
·
Aug 25

Barings Corporate Investors Q2 Dividend USD 0.4

THOMSON REUTERS
·
Aug 15

Press Release: Barings Corporate Investors Reports Preliminary Second Quarter 2025 Results and Announces Quarterly Cash Dividend Of $0.40 Per Share

Dow Jones
·
Aug 15

India Wholesale Price Index Deflation Deepens in July

MT Newswires Live
·
Aug 14

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

GlobeNewswire
·
Jul 30